Results 151 to 160 of about 2,667 (188)

Early Myasthenia Gravis Activities of Daily Living (MG-ADL) Response to Ravulizumab in Acetylcholine Receptor-Positive Generalized Myasthenia Gravis Refractory: A Case Report From Latin America. [PDF]

Cureus
Orellana M, Bustamante G.
europepmc   +1 more source

Thymoma Associated Myasthenia Gravis Successfully Treated With Ravulizumab

Muscle & Nerve
Vasiliki Zouvelou, Ioanna Tatouli, Loukas Lymperopoulos, Eleni Strataki, Dimitra Tzavella, Christina Vourlakou, Charalampos Zisis, Sofoklis Kontogiannis   +7 more
openaire   +3 more sources

Progress in the Treatment of Refractory Myasthenia Gravis. [PDF]

Rev Neurol
Liu D, Mao J, Song J, Wang M.
europepmc   +1 more source

Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy. [PDF]

Blood Adv
Padilla Kelley T, King H, Malhotra A, DeLoughery TG, Martens K, Shatzel JJ.   +5 more
europepmc   +1 more source

Ravulizumab for paroxysmal nocturnal haemoglobinuria.

Australian prescriber
openaire   +1 more source

Iptacopan for paroxysmal nocturnal haemoglobinuria. [PDF]

Aust Prescr
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Monitoring Ravulizumab effect on complement assays

Journal of Immunological Methods, 2021
Ravulizumab is a new C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the
Maria A V, Willrich, Paula M, Ladwig, Mark A, Martinez, Meera R, Sridharan, Ronald S, Go, David L, Murray   +5 more
openaire   +2 more sources